Introduction
Embryonal rhabdomyosarcoma (ERMS) is a malignant tumour of mesenchymal origin and one of the most common extra-cranial solid tumours of childhood. ERMS tends to affect children within the first decade of life and the more common sites are orbit, nasopharynx, vagina and bladder. The majority of ERMS arise sporadically, but associations between ERMS and inherited familial syndromes, such as the Li-Fraumeni syndrome, neurofibromatosis and Beckwith-Weidemann syndrome suggest that a genetic predisposition contributes to some cases [1] [2] [3] [4] [5] .
Recently it has become evident that some ERMS are associated with germ-line DICER1 mutations. In general, DICER1 mutations cause a distinctive tumour predisposition syndrome, the DICER1 syndrome, (OMIM # 601200) which is characterized by pleuropulmonary blastoma (PPB) and other rare childhood neoplasms 6 . PPB is a mixed pattern sarcoma in which ERMS is a predominant histologic subtype 7 .
DICER1 mutations are strongly associated with ERMS of the uterine cervix (cERMS), a generally uncommon site for ERMS, which occurs from the age of approximately 10-20 years 5, 8, 9 . Both germ-line and highly characteristic somatic "hotspot" DICER1 mutations have been reported in two cERMS 8, 10 and bladder ERMS has been observed in two DICER1 kindred 7, 11 . DICER1 mutations were identified in two of 52 sporadic ERMS cases 7 . No associations are evident between DICER1 mutations and alveolar rhabdomyosarcoma (ARMS), a rhabdomyosarcoma subtype tending to affect older children and believed to arise through biological mechanisms distinct from ERMS 12 .
Like cERMS, ovarian ERMS (oERMS) is particularly rare 13 ; a case of oERMS, which was histologically similar to cERMS and potentially associated with a DICER1 mutation, has been mentioned in the literature 5, 14 , but the child's mutation status was not reported. We report detailed investigation of DICER1 gene in a six-year-old girl with oERMS and other DICER1 phenotypes.
Materials and Methods
The study was approved by the Institutional Review Board of the Faculty of Medicine of McGill University no. A12-M117-11A and was performed with full informed parental consent. The tumours were reviewed by pathologists at the institution from which the samples were acquired and by central reference pathologists (JA and DB-DS).
Molecular Screening of DICER1: Somatic "hotspot" mutations affecting the RNase IIIa and RNase IIIb domains were screened for by PCR amplification of gDNA extracted from each of the formalin-fixed, paraffin-embedded (FFPE) tumours, followed by Sanger sequencing (McGill University and Genome Quebec Innovation Centre (MUGQIC)), as previously described [15] [16] [17] . Myogenin mouse monoclonal antibody (Dako) were used without further dilution.
Case Report and results
A six-year-old girl of Ashkenazi Jewish and Anglo-Saxon descent presented with a three month history of abdominal distension, rigidity and difficulty passing urine. A mass on the right ovary was discovered, measuring 11.5 cm x 10 cm x 7 cm ( Fig. 1a ). Surgical resection of the right ovarian tumour, right fallopian tube and part of the omentum was performed and she was treated with antinomycin D, vincristine and cyclophosphamide in conjunction with etoposide and ifosfamide therapy. She also received whole abdomen radiation 1800 cGy in 12 fractions. Pathology of the multiloculated mass showed variability in architecture and differentiation: an edematous myxoid matrix containing small (Fig. 3a) . We confirmed this mutation and also identified an acquired somatic mutation in the oERMS tumour gDNA: c.5425G>A mutation, which is predicted to result in p.(Gly1809Arg) at the protein level (Fig. 3b, Panel I) . A different somatic DICER1 mutation, c.5439G>T, predicted to cause p.(Glu1813Asp) at the protein level, was identified in the CN tumour gDNA (Fig. 3b, Panel III) . Both somatic mutations are predicted to be damaging by both SIFT and PolyPhen2 with respective scores of 0 [0.02 for the p.(Gly1809Arg) mutation] and 1. No tissue was available for molecular analysis from the MNG or the fibroadenoma.
Discussion
Ovarian tumours associated with the DICER1 syndrome are predominantly non-epithelial in origin. SLCT (a non-epithelial ovarian sex-cord stromal tumour) is the most frequently observed ovarian tumour in DICER1 mutation carriers 14, 15 and somatic DICER1 missense mutations occurring within the RNase IIIb domain have been identified in 60% of ovarian SLCTs 10, 15 . Other ovarian sex cord-stromal tumours reported with a DICER1 mutation include juvenile granulosa cell tumour and gynandroblastoma 14, 15 . The age of onset for DICER1-associated SLCT typically ranges from 2 to 45 years of age with a peak onset between 10 and 15 years of age 6 . We sought to determine the approximate range for age of susceptibility for oERMS tumours. Our literature search (summarised in Supplementary Table S1) revealed 32 welldocumented reports of ovarian rhabdomyosarcomas, nineteen of which are of the embryonal subtype. The ages at first symptom report of the ERMS cases ranged from 6 to 86 years of age, with a median age of 25 years. The oERMS case we report presented at 6 years of age. It remains to be seen whether oERMS occurring in association with a DICER1 mutation tend to present at an earlier age, as is the case for the majority of the DICER1-associated diseases 6 . The cystic nephroma, a common DICER1 phenoptype, in the patient we report is particularly notable because the 2.1 cm-diameter CN is documented to have developed at age 12 years during a 7-month interval between surveillance magnetic resonance scans (Fig.   1b , panels I and II). Almost all DICER1-associated CN are diagnosed before age 4 years 18, 19 ; in rare CN cases diagnosed at an older age, the age at which the CN actually developed is uncertain. Documented development of CN at age 12 years is unprecedented and illustrates the challenges of disease screening in DICER1 mutation carriers. The CN contained a somatic RNase IIIb mutation, discussed below, which is typical for CN 20 . This child had received 1800 cGy total abdominal radiation 6 years prior to development of CN. There is, however, no suggestion in the literature that therapeutic doses of ionizing radiation might predispose to development of CN or to DICER1 RNase IIIb mutations.
The somatic mutations identified within the oERMS (c.5439G>T) and CN (c.5425G>A) tumour samples are typical of somatic mutations in other DICER1 phenotypes 6 and occurred within the sequence encoding the RNase IIIb domain of DICER1, affecting highly conserved amino acid residues. The DICER1 protein is a small RNA processing endoribonuclease, which measures and cleaves microRNA (miRNA) hairpin precursors to generate mature miRNAs, which subsequently regulate the translation of target-gene mRNA transcripts. The amino acids altered by the mutations (Gly1809 and Glu1813) are metal-ion binding residues central to the cleavage of 5p miRNAs from the 5′ arm of miRNA precursors (pre-miRNAs).
Mutations of these RNase IIIb sites disrupt the processing of pre-miRNAs and consequently reduce the population of 5p miRNAs within the cell 21, 22 . As has recently been reported 23 , we noted the occurrence of two different somatic DICER1 RNase IIIb mutations in two tumours that arose in the patient. oERMS has striking histologic similarities, including primitive cartilage elements, to other distinctive DICER1-related tumours like PPB and cERMS 5 , which points to a common histological origin and genetic cause. The discovery of a somatic RNase IIIb DICER1 mutation in an oERMS arising in a germline mutation carrier adds to the growing literature that these RNase IIIb mutations are key mutational events in DICER1-related tumourigenesis. The downstream perturbations of miRNA biogenesis that arise in cells in which DICER1 function is impaired are currently being explored and the underlying 9 mechanisms of tumourigenesis are being investigated. Sequencing of DICER1 in additional oERMS tumours may further substantiate this tumours' association with the DICER1 syndrome.
Conclusion
This report documents both germ-line and highly characteristic somatic DICER1 mutations in a case of oERMS, suggesting that oERMS is among the growing list of rare childhood tumours associated with the DICER1 syndrome. Screening for DICER1 mutations should be considered for children presenting with this rare condition. This report also documents an unusually late presentation of CN at the age of 12 years.
Taken together with the primary finding of an oERMS, this finding shows that the clinical phenotype associated with DICER1 mutations remains unsettled. 
